Advertisement


Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC

ASCO 2026

Advertisement

Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radiotherapy. C-POST evaluated adjuvant cemiplimab-rwlc for patients with high-risk cutaneous squamous cell carcinoma (CSCC) (Abstract 6083).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The C-POST trial is a phase 3 trial in patients with high-risk cutaneous squamous cell carcinoma. They compared adjuvant cemiplimab with placebo. In this trial, patients who had high-risk cutaneous SCC were randomized to either receive cemiplimab for 48 weeks or placebo. These patients had to have had surgery with complete macroscopic resection and have completed radiotherapy. This was a positive trial with clinically meaningful and statistically significant results: a hazard ratio of 0.32 and a P value of less than .001. So, a 68% reduction in the risk of disease recurrence or death, and this included a decrease in risk of locoregional recurrence and distant recurrences. At this ASCO meeting, we presented further analysis to better understand the benefits of cemiplimab as an adjuvant treatment in this population. In the C-POST trial, patients were selected based on high-risk criteria. These high-risk criteria could be nodal, such as having a lymph node that was greater than 2 cm with extranodal extension or more than 3 nodes, or several high-risk nonnodal criteria, such as in-transit metastases, T4 disease, perineural invasion, if there was involvement clinically or radiologically, or recurrent disease with other high-risk features. So what we wanted to see in these further analyses is whether all of these groups conveyed a disease-free benefit with cemiplimab compared with placebo. So we looked at all of these nodal and nonnodal criteria, and in fact, in every single group, there was similar disease-free benefit with cemiplimab versus placebo. The other thing that we looked at was the interval between completion of radiation and randomization. The protocol stipulated that patients had to start treatment or at least be randomized between 2 and 11 weeks after completing their radiotherapy. The median was 5.6 weeks. So we looked at the group that started within 2 to 6 weeks and the group that started in 6 to 11 weeks. And in fact, there was a similar disease-free benefit, irrespective of the interval since radiation. These analyses were conducted with updated follow-up, with a median follow-up of 30 months, and the overall disease-free benefit is still significant at 0.335. These results further reinforce that this benefit from adjuvant cemiplimab was seen in all the high-risk groups and irrespective of the interval from radiation. Further follow-up is ongoing of the C-POST trial, and longer-term follow-up and survival analysis will be presented at a later date.

Related Videos

Prostate Cancer

Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide

Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).

Gynecologic Cancers

Ramez N. Eskander, MD, on Endometrial Cancer: Pembrolizumab Plus Carboplatin/Paclitaxel

Ramez N. Eskander, MD, of UC San Diego Moores Cancer Center, presents an updated overall survival analysis and examination of subsequent therapy in patients with endometrial cancer treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG-GY018 trial (Abstract 5502). 

Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer

Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).  

Lymphoma

Manali Kamdar, MD, on Rapid Oral Abstract Highlights: Three Emerging Trends in Lymphoma Care

Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell lymphoma, continued development of cellular therapies, and expanding molecular profiling. 

Prostate Cancer

Atish Choudhury, MD, PhD: Can Patients With an Exceptional Response to ARPIs Interrupt ADT?

Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004). 

Advertisement

Advertisement




Advertisement